Stanford Medicine researchers have recently introduced an innovative artificial intelligence (AI) model named MUSK (multimodal transformer with unified mask modeling) that significantly improves the accuracy of cancer prognosis predictions. By integrating both visual and textual medical data, this
Groundbreaking research conducted by a collaborative team from Mount Sinai and Memorial Sloan Kettering Cancer Center has unveiled a novel mechanism by which monoamine neurotransmitters, specifically serotonin, dopamine, and histamine, regulate brain physiology and behavior. This research
Geneoscopy, Inc., a life sciences company dedicated to advancing gastrointestinal health, has recently achieved an impressive milestone by securing a Series C funding round that amassed $105 million. This significant investment, led by Bio-Rad Laboratories and supported by various prominent
The field of drug discovery has long been challenged by the concept of "undruggable" targets—proteins and pathways that are crucial in disease processes but difficult to target with traditional small molecule drugs. One particularly challenging target is β-catenin, a key player in the Wnt/β-catenin
Imagine a world where cancer patients could receive personalized treatment precisely tailored to their unique biological makeup, drastically improving their chances of success. This once-idealistic vision is now becoming a reality with the advent of SCORPIO, an innovative AI-driven tool developed
Glioblastoma, an aggressive and often fatal form of brain cancer, has long posed a formidable challenge to medical professionals. With an average lifespan of 12 to 15 months post-diagnosis and a mere 5% survival rate five years after diagnosis, the need for innovative treatments has never been more
